| Literature DB >> 22242207 |
Nicholas E Kman1, Daniel J Bachmann.
Abstract
Since the terrorist attacks and anthrax release in 2001, almost $32 billion has been allocated to biodefense and biosurveillance in the USA alone. Surveillance in health care refers to the continual systematic collection, analysis, interpretation, and dissemination of data. When attempting to detect agents of bioterrorism, surveillance can occur in several ways. Syndromic surveillance occurs by monitoring clinical manifestations of certain illnesses. Laboratory surveillance occurs by looking for certain markers or laboratory data, and environmental surveillance is the process by which the ambient air or environment is continually sampled for the presence of biological agents. This paper focuses on the ways by which we detect bioterrorism agents and the effectiveness of these systems.Entities:
Year: 2012 PMID: 22242207 PMCID: PMC3254002 DOI: 10.1155/2012/301408
Source DB: PubMed Journal: Adv Prev Med
Characteristics of bioterrorism-related epidemics that affect detection through clinical recognition versus syndromic surveillance.
| Characteristicsa | Clinical recognitionb | Syndromic surveillancec |
|---|---|---|
| Duration and variability of incubation period | Broader distribution of incubation period increases likelihood that patients with short incubation-period disease would be diagnosed before a statistical threshold of syndromic cases is exceeded. | More narrow distribution of incubation period which leads to a steeper epidemic curve in the initial phases increase likelihood that statistical threshold would be exceeded sooner. |
| Duration of nonspecific prodromal phase | Shorter prodrome increases likelihood of recognition or diagnosis at more severe or fulminant stage. | Longer prodrome increases likelihood that increase in syndromic manifestations would be detectable and that recognition of more severe stage (at which a diagnosis is more apt to be made) would be delayed. |
| Presence or absence of clinical sign that would heighten suspicion of diagnosis | Presence increases likelihood of earlier clinical recognition and diagnosis (e.g., mediastinal widening on chest X-ray in inhalational anthrax or multiple cases of rare disease presenting at similar time). | Absence decreases likelihood that diagnosis would be considered clinically, increasing opportunity for earlier detection by means of syndromic surveillance. |
| Likelihood of making diagnosis in the course of routine clinical evaluation | If diagnosis is apt to be made in the course of a routine diagnostic evaluation (not dependent on clinical suspicion of specific bioterrorism infection), early diagnosis through clinical care is likely. | If diagnosis is dependent on the use of a special test that is unlikely to be ordered in the absence of clinical suspicion of diagnosis, then diagnosis in clinical care may be delayed, increasing the opportunity for early detection through syndromic surveillance. |
aInfection or disease attributes that may affect detection of an epidemic.
bIncreases likelihood of initial detection through routine clinical care and reporting.
cIncreases likelihood of initial detection through syndromic surveillance.
Laboratory divisions within the laboratory response network.
| Level A Laboratory (Sentinel Labs) | Tier 1 | Approximately 2300 hospital and clinic labs were likely first to receive specimens. Role is to rule out and refer to a lab within LRN to confirm a diagnosis. |
| Level B Laboratory (Reference Labs) | Tier 2 | Increased capabilities to confirm diagnoses of biological agent. County public health labs where role is confirmatory testing, initial susceptibility testing, and referral. |
| Level C Laboratory (Reference Labs) | Tier 2 | Much like level B, State public health labs that confirm diagnosis and refer to national laboratory. There are approximately 160 reference labs (B and C). |
| Level D Laboratory (National Labs) | Tier 3 | National laboratories whose primary responsibility is to further characterize the agent (CDC, USAMRIID have biosafety level IV (BSL-4) capabilities). |